Can the p70 S6 kinase recombinant rabbit monoclonal antibody analyze the mTOR signaling hub?

Concept

p70 S6 Kinase (p70S6K), a serine/threonine kinase of the AGC superfamily, serves as a pivotal downstream effector of the mammalian target of rapamycin complex 1 (mTORC1) and a core nodal molecule within the mTOR signaling hub. It exists in two highly homologous isoforms, S6K1 and S6K2, encoded by distinct genes, and modulates core cellular processes including protein synthesis, cell growth, metabolic homeostasis and cell cycle progression via the phosphorylation of ribosomal protein S6 and a diverse array of downstream substrates.

The activation of p70S6K is co-regulated by mTORC1-mediated phosphorylation modifications and synergistic signaling inputs from the phosphoinositide 3-kinase (PI3K) pathway. Under physiological conditions, its activity is tightly controlled; in pathological states, aberrant activation of the p70S6K signaling axis is closely associated with the initiation and progression of various cancers. S6K1 gene amplification and overexpression are frequently observed in breast, ovarian and gastric cancers, and correlate strongly with poor patient prognosis. The p70 S6 Kinase Recombinant Rabbit Monoclonal Antibody is an indispensable research tool that enables accurate detection of p70S6K in different activation states and subcellular localizations, laying a critical foundation for elucidating the functional mechanisms of the mTOR signaling hub in tumor biology and beyond.

Research Frontier

Current research on the mTOR signaling hub and p70S6K is advancing at the intersection of molecular cell biology, tumor immunology and translational medicine, with several key cutting-edge directions defining the field:

1. p70S6K as a cancer prognostic biomarker and therapeutic target: Research is focused on clarifying the precise oncogenic mechanisms of p70S6K isoforms and developing S6K-specific inhibitors, with the goal of translating these findings into targeted anti-tumor therapies that address the limitations of current mTOR pathway drugs.
2. Precision antibody engineering for p70S6K detection: A major research focus is the development of antibodies that distinguish total p70S6K from its phosphorylated active forms (Thr229, Thr389) and isoform-specific antibodies for S6K1/S6K2, as well as reagents optimized for formalin-fixed paraffin-embedded (FFPE) tumor tissue analysis to support clinical translational research.
3. mTOR signaling analysis in 3D tumor organoid models: Tumor organoids, which preserve the native tissue architecture and cellular heterogeneity of primary tumors, have become a gold standard for physiologically relevant mTOR pathway research. Researchers are leveraging p70S6K antibodies to map the spatial and dynamic activation of the mTOR signaling hub in organoids for more accurate drug screening and mechanism validation.
4. Unraveling mTOR signaling network feedback and drug resistance: A key frontier is defining the complex feedback regulation and inter-pathway crosstalk within the mTOR-p70S6K axis, and identifying compensatory bypass signaling pathways that drive acquired resistance to mTOR inhibitors in tumor cells.
5. Multi-platform application of p70S6K antibodies in drug development: The integration of p70S6K antibodies into high-throughput screening systems, phosphorylation-specific ELISA assays and in vivo tumor tissue analysis is accelerating the development and preclinical evaluation of mTOR/S6K pathway-targeted drugs, with a focus on improving target engagement assessment and efficacy validation. 

Research Significance

Elucidating the role of p70S6K in the mTOR signaling hub and developing high-quality p70 S6 Kinase Recombinant Rabbit Monoclonal Antibodies hold profound scientific and translational significance across multiple research fields:

• Mechanistic research of the mTOR signaling network: p70S6K is a direct and reliable readout of mTORC1 activity, and specific antibodies enable precise detection of its activation state, subcellular localization and protein-protein interactions. This provides critical insights into the regulatory mechanisms of the mTOR signaling hub and its cross-talk with other oncogenic pathways (PI3K/Akt, MAPK/ERK).
• Tumor biology and oncology research: Abnormal p70S6K activation is a hallmark of many human cancers, and p70S6K antibodies facilitate the characterization of this kinase’s role in tumor cell proliferation, metabolic reprogramming, invasion and metastasis. They also support the validation of p70S6K as a prognostic biomarker for cancer patients, advancing personalized oncology research.
• Preclinical and clinical anti-tumor drug development: p70S6K antibodies are essential tools for evaluating the efficacy of mTOR/S6K pathway inhibitors at all stages of drug development—from in vitro cell-based assays and 3D organoid screening to in vivo animal models and clinical tumor tissue analysis. They enable quantitative assessment of target engagement and the identification of drug resistance mechanisms, accelerating the translation of novel therapeutics to the clinic.
• Basic cell biology research: Beyond oncology, p70S6K is a key regulator of normal cell growth, protein synthesis and metabolic homeostasis. Antibodies against p70S6K support fundamental research into these core cellular processes, with important implications for the study of metabolic diseases, neurodegenerative disorders and stem cell biology.
• Advancement of biological detection methodologies: The development of highly specific and sensitive p70 S6 Kinase Recombinant Rabbit Monoclonal Antibodies sets a benchmark for antibody engineering targeting post-translationally modified kinases, advancing detection methodologies for Western Blot, immunofluorescence, immunohistochemistry and flow cytometry across the life sciences.

Related Mechanisms and Product Applications

Core Mechanisms of p70S6K in the mTOR Signaling Hub

p70S6K acts as the primary effector molecule of mTORC1, with its activation dependent on hierarchical phosphorylation at two key conserved residues: Thr229 in the activation loop and Thr389 in the hydrophobic motif. These phosphorylations are mediated by mTORC1 and the PI3K/Akt signaling pathway, and are essential for the kinase’s enzymatic activity.

Once activated, p70S6K phosphorylates ribosomal protein S6, which in turn upregulates cap-dependent mRNA translation and promotes the synthesis of proteins required for cell growth, proliferation and metabolic activity. Structurally, p70S6K comprises an N-terminal domain, a highly conserved kinase domain and a C-terminal domain; its functional activity is tightly linked to post-translational modifications (primarily phosphorylation) and specific protein-protein interactions. The conserved kinase domain is the primary target for the development of specific antibodies and small molecule inhibitors, as its sequence conservation across species ensures cross-species recognition and minimal off-target effects.

The mTOR-p70S6K signaling axis is a key regulator of cellular homeostasis, responding to nutrient availability, growth factors and cellular stress signals. In cancer, constitutive activation of this axis drives uncontrolled cell proliferation and survival—a core hallmark of tumorigenesis—making p70S6K a critical therapeutic target for anti-tumor drug development.

Key Molecular Features for p70S6K Antibody Design

The development of high-performance p70 S6 Kinase Recombinant Rabbit Monoclonal Antibodies requires careful consideration of the kinase’s structural and functional molecular features:

1. Discrimination of protein forms: Antibodies must distinguish between total p70S6K protein and its phosphorylated active forms (Thr229, Thr389); pan-specific antibodies target conserved sequences for expression level detection and immunoprecipitation, while phosphorylation-specific antibodies recognize modified key activation sites for functional activity analysis.
2. Isoform specificity: S6K1 and S6K2 exhibit sequence differences, so isoform-specific antibody development requires the selection of unique antigenic regions for each isoform to avoid cross-reactivity.
3. Immunogen design: Recombinant proteins or synthetic peptides used as immunogens must cover different structural domains and post-translational modification states of p70S6K to enrich the diversity of antibody clones and ensure the generation of functional antibodies.
4. Leverage of rabbit immune system: The rabbit immune system has a unique antibody maturation mechanism that enables the production of high-affinity antibodies capable of recognizing conformational epitopes and post-translational modification-dependent epitopes, which is critical for detecting the native form of p70S6K.
5. FFPE tissue compatibility: For immunohistochemical applications in tumor research, antibodies must withstand formalin fixation and paraffin embedding, and recognize epitopes that remain stable under cross-linking conditions to enable reliable detection in clinical tumor samples.

Broad Applications of ANT BIO PTE. LTD.’s p70 S6 Kinase Recombinant Rabbit Monoclonal Antibody

ANT BIO PTE. LTD.’s p70 S6 Kinase Recombinant Rabbit Monoclonal Antibody (Starter sub-brand, Product No.: S0B0875) is engineered with high specificity, high affinity and excellent stability, targeting the conserved kinase domain of p70S6K (S6K1, encoded by the RPS6KB1 gene) and enabling specific recognition of p70S6K total protein across multiple species. Validated for use across a diverse range of experimental platforms, this antibody is a core research tool for mTOR signaling hub research, with its key applications including:

1. Analysis of mTOR Signaling in Tumor Organoid Models

Tumor organoids are a revolutionary 3D culture model that retains the tissue architecture and cellular heterogeneity of primary tumors, making them an ideal platform for mTOR pathway research and drug screening. This antibody enables comprehensive analysis of mTOR signaling activation at the organoid level:

• It supports immunofluorescence staining to detect the spatial distribution of p70S6K and its phosphorylated forms in different organoid subregions, revealing characteristic patterns such as higher S6 phosphorylation in the nutrient-rich peripheral proliferative zone and weaker signaling in the nutrient-limited central zone.
• In drug intervention experiments, it quantifies changes in phosphorylated S6 levels to evaluate the efficacy of mTOR inhibitors and S6K-specific inhibitors, establishing direct correlations between target engagement and organoid growth inhibition.
• In gene-edited organoid models, it verifies the knockout efficiency of S6K1/S6K2 and uncovers signal compensation mechanisms within the mTOR signaling hub.
• In organoid-immune cell co-culture systems, it can be combined with immune cell marker antibodies to elucidate the molecular basis of crosstalk between tumor-intrinsic mTOR signaling and the tumor immune microenvironment.

2. Elucidation of mTOR Signaling Network Regulatory Mechanisms

The activation state of p70S6K directly reflects the upstream signaling input intensity and feedback regulation of the mTOR signaling hub, and this antibody is a powerful tool for unraveling the complex regulatory network of mTOR signaling:

• It facilitates immunoprecipitation combined with mass spectrometry analysis to identify the composition of p70S6K-interacting protein complexes, uncovering novel regulatory partners and downstream effectors of the mTOR pathway.
• Paired with high-resolution cellular imaging techniques, it resolves the spatiotemporal dynamics of p70S6K—including its rapid phosphorylation and translocation to the cell membrane and perinuclear regions upon insulin or growth factor stimulation.
• In drug resistance research, it detects the reactivation of the S6K signaling pathway in tumor cells with acquired resistance to mTOR inhibitors; by comparing p70S6K phosphorylation levels between sensitive and resistant clones, it reveals compensatory mechanisms involving bypass signaling activation.

3. Support for Anti-Tumor Drug Development and Efficacy Evaluation

As a key target in anti-tumor drug development, p70S6K requires reliable research tools to assess target engagement and inhibitor selectivity, and this antibody serves as a core reagent for all stages of mTOR/S6K pathway drug development:

• It is used to construct phosphorylation-specific ELISA systems for the quantitative measurement of p70S6K activity changes following inhibitor treatment, enabling high-throughput screening of potential drug candidates.
• In cell-level efficacy evaluations, it is combined with downstream substrate S6 phosphorylation detection to establish robust correlations between target engagement and tumor cell proliferation inhibition.
• In organoid-based high-throughput drug screening, it supports imaging-based analysis to assess the inhibitory effects of compound libraries on the S6K signaling pathway.
• In in vivo preclinical studies, it is used for immunohistochemical staining of tumor tissues to evaluate the potency and duration of action of mTOR/S6K inhibitors on the p70S6K signaling pathway.
• It screens synergistic combination therapy strategies by detecting the additive inhibitory effects of different drug combinations on p70S6K phosphorylation and downstream signaling networks, providing experimental evidence for optimizing anti-tumor treatment regimens.

4. Multi-Platform Basic and Translational Research

Validated for use in Western Blot (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry (IHC) and flow cytometry (Flow), this antibody supports comprehensive p70S6K detection and functional analysis across diverse experimental scenarios:

• It enables sensitive and accurate detection of p70S6K expression and activation levels in cell lines, primary cells and FFPE tumor tissues across multiple species (human, mouse, rat).
• Its minimal cross-reactivity to S6K2 and other AGC family kinases (Akt, PKC, RSK) ensures accurate and reliable results in complex biological samples.
• Its high affinity and low background signal deliver consistent performance in both qualitative and quantitative assays, making it a core tool for mTOR signaling pathway research, protein synthesis regulation, cell growth and metabolism research, and metabolic disease research.

Core Product Advantages

Professional Technical Support

ANT BIO PTE. LTD. provides comprehensive and expert technical support for the p70 S6 Kinase Recombinant Rabbit Monoclonal Antibody, including detailed product technical documentation covering:

• Specificity validation data (cross-reactivity analysis with S6K2 and other AGC family kinases)
• Species cross-reactivity validation data (human, mouse, rat, etc.)
• Multi-platform application recommendations (optimized WB/IP/IF/IHC usage conditions)
• Typical application examples (tumor tissue IHC staining, mTOR signaling pathway research data)

Our professional technical team offers efficient support for experimental design, mTOR signaling pathway research, tumor metabolism analysis, and anti-tumor drug mechanism studies, ensuring the success of your research projects.

ANT BIO PTE. LTD. has established a mature and advanced rabbit immunization and single B-cell antibody development platform, covering the entire R&D process from rational antigen design and immunization strategy optimization to single B-cell high-throughput sorting, antibody gene cloning, recombinant expression, and multi-application validation. We provide systematic antibody customization solutions for various research application scenarios, tailored to meet the specific research needs of the global scientific community.

Brand Mission

At ANT BIO PTE. LTD., our core mission is to empower life science breakthroughs by developing and providing high-quality, innovative and reliable biological reagents and comprehensive research solutions for scientists and researchers worldwide. Leveraging our advanced recombinant antibody development platforms—including a state-of-the-art rabbit immunization and single B-cell sorting system—and rigorous quality control protocols, we engineer cutting-edge research tools for key signaling molecules such as p70S6K, addressing the critical research needs of the scientific community in cancer biology, cell signaling, metabolic research and anti-tumor drug development.

Our three specialized sub-brands form a comprehensive and integrated product ecosystem that covers the full spectrum of life science research needs, supporting every stage of the experimental workflow from basic molecular mechanistic research to preclinical translational development:

• Absin: Specializes in high-quality general life science reagents and research kits, including molecular biology, cell biology and immunology reagents, providing essential experimental tools for sample preparation, signal detection and functional validation in mTOR signaling pathway research.
• Starter: Our flagship antibody sub-brand, focused on the development of premium polyclonal, monoclonal and recombinant antibodies—including the p70 S6 Kinase Recombinant Rabbit Monoclonal Antibody. Starter antibodies are engineered for high specificity, high affinity and multi-platform versatility, rigorously validated for various research applications and designed to meet the rigorous demands of basic scientific research and clinical translational research.
• UA: Dedicated to the development and production of high-purity recombinant proteins, including cytokines, growth factors and key signaling molecules, providing research-grade reagents for cell culture, pathway activation and in vitro functional assays in mTOR signaling and cancer biology research. 

We are committed to being a trusted and reliable research partner for scientists worldwide, providing not only superior quality biological reagents but also personalized technical support and solution design. By prioritizing innovation, quality and customer-centricity, we accelerate the pace of scientific discovery and the development of novel therapeutic strategies for human diseases, bridging the critical gap between basic scientific research and clinical translation.

Related Product List

Disclaimer

This article was partially created with the assistance of artificial intelligence. If any content involves copyright or intellectual property issues, please inform us, and we promise to verify and remove it immediately.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.